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tration of edaravone at 10 min before reperfusion and immediately after reperfusion had
a cardioprotective effect against ischemia-reperfusion injury, but the treatment with edar-
avone at 5 min after reperfusion did not show this protective effect.
1078-98 Transplantation of Autologous Bone Marrow 
Mononuclear Cells Does Not Alter Arrhythmia 
Threshold in Adult Swine With Chronic Myocardial 
Ischemia
Fernando Tondato, Aysegul Yegin, Jianhua Cui, Mio Ebato, Bunken Ebato, Steve 
Frohwein, Jesse Rios, Keith Robinson, Nicholas Peters, James Sanzo, Traci Goodchild, 
Mark Ungs, Nicolas Chronos, American Cardiovascular Research Institute, Atlanta, GA
Background: Bone marrow-derived mononuclear cells (BM-MNCs) can give rise to endot-
helial progenitor cells and localized transplantation of BM-MNCs in ischemic myocardium
may augment neovascularization. However, not much is known of the arrhythmogenic
potential of BM-MNCs after intramyocardial transplantation. Objective: Evaluate the
threshold for ventricular arrhythmia induction with conventional electrophysiologic study
(EPS) with programmed stimulation in swine with chronic myocardial ischemia treated
with autologous BM-MNCs. Methods: Adult Yucatan swine underwent left circumflex
(LCX) ameroid implantation. At 4 weeks, animals were randomized to receive either BM-
MNCs (n=8) or DMEM culture medium as control (n=8). Bone marrow (30-50ml) was
aspirated from sternum and if necessary, iliac crest. Mononuclear cells were isolated
using density gradient centrifugation. Catheter-based (Boston Scientific StilettoTM)
intramyocardial injections were performed with combined fluoroscopic and intracardiac
echocardiography (ICE) guidance. The treatment group received total of 1 x 108 BM-
MNCs at 10 sites, 5 in ischemic (LCX), and 5 in non-ischemic (LAD) region. Four weeks
after cell treatment, global wall motion score index (GWMSI) was evaluated by dob-
utamine stress echocardiography. Subsequently, electrophysiologic study was performed
with right ventricle stimulation at apex and outflow tract, using a basic cycle length of 500
and 400msec and 1-3 extrastimuli. Results: No difference was found in total number of
cases with inducible arrhythmias in BM-MNC and control groups: 3 out of 8 animals
(38%) in BM-MNC group (2 polymorphic VT and 1 VF) and 3 out of 8 animals (38%) in
control group (1 monomorphic VT and 2 VF). There was also no difference in global wall
motion (GWMSI=1.03 in BM-MNCs; 1.17 in sham, p=0.38) and there was no correlation
between GWMSI and ventricular arrhythmia induction (1.29 for induced pigs; 1.01 for
non-induced, p=0.09). Conclusion: Transplantation of autologous BM-MNCs into
ischemic myocardium did not alter the threshold for ventricular arrhythmia. Left ventricu-
lar dysfunction was not related to arrhythmia inducibility.
1078-99 Monocyte Chemoattractant Protein-1 Induced Monocyte 
Infiltration and Angiogenesis Does Not Result in 
Arteriogenesis or Improved Cardiac Function in 
Chronically Infarcted Myocardium
Ernst R. Schwarz, Dennis A. Meven, Philipp H. Kersting, Tanja Tussing, Erik C. Skobel, 
Peter Hanrath, The University of Texas Medical Branch, Galveston, TX, Rheinisch 
Westfaelische-Technische Hochschule, Aachen, Germany
Monocyte chemoattractant protein 1 (MCP-1) stimulates invasion of monocytes into
ischemic tissue with concomitant adhesion to endothelial cells. This process has been
shown to be involved in the induction of arteriogenesis, i.e., the development of functional
arterioles resulting in improvement of perfusion in contrast to angiogenesis without
changes in blood flow. The effects of MCP-1 on angiogenesis and arteriogenesis and
changes of left ventricular function were tested in infarcted rat hearts. Anesthesized rats
were subjected to open-chest ligation of the left coronary artery with subsequent myocar-
dial infarction. After six weeks, animals were randomized to receive either MCP-1 (3µl in
0.15ml NaCl, group1, n=9) or saline (0.15ml, group 2, n=9), which was injected after tho-
racotomy into the myocardium at the infarct border zones. Transthoracic echocardio-
graphy was performed for assessment of left ventricular dimensions and cardiac function
(ejection fraction, EF) at baseline, six weeks after myocardial infarction, and four weeks
after MCP-1 or saline injection, by use of a 12 MHz pediatric transducer. For microscopic
analysis, myocardial tissue was stained by Elastica-van-Giesson and von-Willebrand fac-
tor for blood vessels and endothelial cells, respectively. In a subset of animals, hearts
were excised 24 hours after MCP-1 (n=4) or saline (n=4) administration for assessment
of monocyte infiltration by staining of the CD 31 antigen. EF decreased from 60±3% to
25±5% in group 1 (p<0.005) and from 58±2% to 26±4% in group 2 (p<0.005) after coro-
nary occlusion, without further changes four weeks after treatment (EF 26±3% in group1,
EF 25±5% in group 2). At the injection site, 391±10 endothelial cells were found in group
1 versus 285±14 in group 2 (p<0.005). Monocyte infiltration was shown in MCP-1 treated
animals but not in saline treated animals. There were 19±2 arteriolar structures in group
1 versus 16±1 in group 2, p>0.05. A single intramyocardial injection of MCP-1 into the inf-
arct border zone induced neo-angiogenesis and monocyte infiltration. MCP-1 injection
did not result in arteriogenesis or functional improvement of chronically infarcted myocar-
dium in this experimental rat model.
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1079-77 Late Angiographic Patency of the Magnetic Vascular 
Port (MVP®) System for Coronary Artery Anastomosis
Uwe Klima, Sven Martens, Gerhard Wimmer-Greinecker, Jan Gummert, Randall Wolf, 
Volkmar Falk, Ricardo A. Costa, Alexandra J. Lansky, Ecaterina Cristea, Roxana Mehran, 
Filip Casselman, Frank van Praet, Hugo Vanermen, Cardiovascular Research 
Foundation, New York, NY
The MVP® System is a magnetic anastomotic coupling system that allows quick and reli-
able connections between a coronary artery and an autologous bypass graft. One mag-
netic clip set (3 miniature magnets) forms a port in the target vessel while a matching
magnetic clip set forms an identical port of opposite polarity in the terminal portion of the
graft vessel. When brought together, the two ports form the anastomosis. This multi-cen-
ter European registry represents the first MVP® clinical experience for anastomosis
between the left anterior descending artery (LAD) and the left internal mammary artery
(LIMA). We report the 6-month angiographic follow-up (FU). Methods: 48 consecutive
patients underwent coronary bypass surgery, including LIMA to the LAD using the MVP®
device. Angiographic FU was performed and the results compared to the graft occlusion
rate for the control arm of the GABI trial (German Angioplasty vs. Bypass Surgery Inves-
tigation), which was 13% at six months of FU. Results: Angiographic results at FU are
shown in the Table. Conclusions: In this European multi-center registry, the MVP® anas-
tomosis device and target vessel patency was 93.8% and 91.7% respectively for anasto-
mosis between the LIMA and LAD at 6 months of FU. The device and target vessel
occlusion rates of 6.2% and 8.3%, were equivalent to the historic control obtained in the
GABI trial (13% occlusion). In addition, there was no evidence of thrombus, ectasia,
aneurysmal dilatation, intimal flap or ulceration in any of the cases at FU.
1079-78 Preoperative QRS Widening and Ventricular 
Dysrhythmia Predict Adverse Outcomes Following Left 
Ventricular Reconstruction for Ischemic 
Cardiomyopathy
Katherine J. Hoercher, Richard Lee, Patrick M. McCarthy, Jingyuan Feng, James B. 
Young, Randall C. Starling, Eugene H. Blackstone, Cleveland Clinic, Cleveland, OH
Objective: Interventions that target the cardiac conduction system such as AICD place-
ment and biventricular pacing improve symptoms and survival in patients with congestive
heart failure.However, the role of the conduction system in outcome after surgical ventric-
ular reconstruction, the excision of dyskinetic and akinetic segments of myocardium,
remains undefined. We reviewed our experience with left ventricular reconstruction (LVR)
in patients with ischemic cardiomyopathy to determine the effect of preoperative conduc-
tion abnormalities on outcome after surgery.
Methods: LVR was performed in 223 pts (80% male, mean age 62± 10 yrs, 66% NYHA
Class III/IV) between 1/97 and 8/02. Mean pre-operative EF was 26 ± 9%. QRS duration
was 122 ± 32msec and an AICD was present in 15%. Time related outcomes considered
were 1) survival, 2) freedom from composite event (transplant, return of NYHA class IV,
and LVAD), and 3) readmission for heart failure. Mean follow-up is 1.5 ± 1.1 yrs.
Results: Survival at 30 days, 1yr, and 3 yrs was 98%, 92%, and 86% respectively.
Patients who had an AICD preoperatively had a higher early mortality (<2 years) (95% vs
77% 2 yrs, p=0.0001). Freedom from composite event was 97%, 89%, and 83%. Patients
who had a prolonged preoperative QRS were more likely to suffer a composite event
(p=0.0002). Freedom from readmission for heart failure was 99%, 80%, and 61% at 30
days, 1 yr, and 3 yrs. Patients with a prolonged preoperative QRS had more frequent
rehospitalizations (p=0.006).
Conclusion: Surgical left ventricular reconstruction in heart failure patients with ischemic
cardiomyopathy yields an encouraging medium term survival and freedom from hospital-
ization for heart failure. Preoperative predisposition to lethal ventricular arrhythmia requir-
ing an AICD was a strong predictor of mortality. This deserves closer examination. Left
ventricular dysynchrony (prolonged QRS) was a strong predictor of residual or recurrent
heart failure and further underscores the importance of ongoing investigations of cardiac
resynchronization therapy as an adjunctive treatment to surgery for heart failure in this
group of at risk patients.
Angiographic Results at 6-month FU
Variable N=48
Device Patency, % (TIMI 3) 45/48 (93.8%)
Target Vessel Patency, % (TIMI 3) 44/48 (91.7%)
Graft Diameter, mm 2.04±0.30
Target Vessel Diameter (Interpolated Normal), mm 1.96±0.32
Bend, degrees 7.08+/-7.43
Tortuosity, % 2/48 (4.2%)
Thrombus/Calcium/Ulceration/Intimal Flap, % 0/48 (0%)
